Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective single-center phase 2 study of denosumab for benign osteolytic bone tumors in adolescents
ChiCTR2000036342Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in benign bone neoplasm, Langerhans cell histiocytosis (LCH), fibrous dysplasia and 1 more, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Bone turnover markers, Progression-free survival and 6 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
benign bone neoplasmLangerhans cell histiocytosis (LCH)fibrous dysplasiaaneurysmal bone cyst (ABC)
Beyond the preview
Go deeper on ChiCTR2000036342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036342.